All In Biotech

Investigational drug · Phase 3

Modified recombinant human C-type natriuretic peptide

Also called: BMN 111

Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Achondroplasia.

Phase 3

Last checked: Nov 20, 2026Latest source record: Mar 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

2

2 still active

All registered trials

10

Any phase or sponsor naming "Modified recombinant human C-type natriuretic peptide"

First trial start

2016

Jan 26, 2016

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Modified recombinant human C-type natriuretic peptide", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Achondroplasia

Approved drugs for the same conditions: Achondroplasia · Rare and genetic disease

Largest trials

Live from ClinicalTrials.gov: studies naming "Modified recombinant human C-type natriuretic peptide" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 7 on PubMed

Also in development for Achondroplasia

  • BMN 333Phase 31 trial

    BioMarin · Achondroplasia

  • KK8398Phase 31 trial

    Kyowa Kirin Co., Ltd. · Achondroplasia

  • DabogratinibTYRA-300Phase 24 trials

    Tyra Biosciences, Inc · FGFR3 Gene Mutation, FGFR3 Gene Alteration, Achondroplasia

  • ABSK061Phase 22 trials

    Abbisko Therapeutics Co, Ltd · HER2-Gastric/Gastroesophageal Junction Cancer, Urothelial Carcinoma, Non-Small Cell Lung Cancer

  • Ascendis Pharma Growth Disorders A/S · Achondroplasia

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from BioMarin.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.